Vivoryon Therapeutics

Update in progress

05Y.F (Frankfurt)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines. Its pipeline targets toxic pGlu-Abeta (N3pE-Abeta) to block its production. The lead candidate PQ912 is a nanomolar QPCT inhibitor that completed Phase IIb for Alzheimer's disease. It also develops the monoclonal antibody PBD-C06 for N3pE-Abeta, with collaborations including Nordic Bioscience, Fraunhofer, and Simcere. Founded in 1997, based in Halle, Germany.

Company score

Sentiment: -0.27; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.09; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive